
Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Summary
Recent clinical trial results indicate that the Wegovy injection successfully reduces body mass index and obesity rates in pediatric patients. The treatment is currently approved for older children, though no pharmaceutical options exist for patients under the age of twelve.
Wegovy is already approved to treat obesity in children ages 12 and older, but there are currently no approved medications for those under 12.
Source: Read the full story at US Top News and Analysis
Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.